Gilead Sciences Stock
Gilead Sciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- CEO
- Daniel O'Day
- Employees
- 17,000
- Market cap
- $193.7 B
- IPO
- 22/01/1992
Gilead Sciences, Inc. is a global biopharmaceutical enterprise headquartered in Foster City, California. Founded in 1987, the company operates across the United States, Europe, and numerous international markets, employing approximately 17,000 employees. The core mission of the firm involves discovering, developing,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Gilead Sciences stock: price history
1D
-0.7%
1W
+3.3%
1M
+5.8%
6M
+13.5%
YTD
+27.3%
1Y
+32.5%
2Y
+80.0%
5Y
+130.9%
10Y
+114.7%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~22% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Double bottom
BullishThe price bounced off a similar low twice, with a rally in between. This W-shaped pattern is a classic reversal signal from a downtrend into an uptrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Gilead Sciences
Analyst assessment of Gilead Sciences
PRICE TARGET LOW
US$126.00
CONSENSUS
US$153.13
MEDIAN
US$161.00
PRICE TARGET HIGH
US$175.00
0
STRONG BUY
38
BUY
19
HOLD
1
SELL
0
STRONG SELL
58
TOTAL · Buy
As of: 08/10/2026
Gilead Sciences stock metrics
P/E
-60.07
P/B
16.41
EV/EBITDA
162.47
RETURN ON EQUITY
-88.7%
NET MARGIN
-134.5%
DEBT/EQUITY
2.22
DIVIDEND YIELD
2.1%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.8%
FLOAT SHARES
1,237,301,651
AVG. DAILY VOLUME (30D)
5,894,649
Insider transactions (SEC)
Mercier Johanna
Dickinson Andrew D
O'Day Daniel Patrick
O'Day Daniel Patrick
Burkhart Erin
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -0.7%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Gilead Sciences stock
What does Gilead Sciences do?
Gilead Sciences, Inc. is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in United States.
The CEO is Daniel O'Day, the company employs around 17,000 people.
The IPO was on 22/01/1992; the stock trades on NASDAQ under the ticker GILD.
What do analysts say about Gilead Sciences stock?
58 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$153.13, ranging from US$126.00 to US$175.00, with a median of US$161.00.
This is an external assessment, not a statement by Market Jury.
When does Gilead Sciences report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 22% stronger than usual.
Does Gilead Sciences pay a dividend?
Yes. The last dividend was US$0.82 per share, ex-date 15/09/2026, paid on 29/09/2026.
The dividend yield is 2.1% (as of 30/06/2026).
Which stocks are comparable to Gilead Sciences?
Comparable stocks include Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck &, Amgen, Pfizer, Bristol-Myers Squibb Company and Biogen.
How can I get Gilead Sciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Gilead Sciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.